Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.550
+0.050 (3.33%)
At close: Jun 24, 2026, 4:00 PM EDT
1.501
-0.049 (-3.14%)
After-hours: Jun 24, 2026, 7:41 PM EDT

Chemomab Therapeutics Stock Forecast

CMMB's stock price has decreased by -67.16% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 2 analysts polled by S&P Global, Chemomab Therapeutics stock has a consensus rating of "Buy" and an average price target of $15. The average 1-year stock price forecast is 867.74% higher than the current stock price, while the lowest is $5.00 (+222.58%) and the highest is $25 (+1,512.90%).

Price Target: $15 (+867.74%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$5.00$15$15$25
Change+222.58%+867.74%+867.74%+1512.9%
* Price targets were last updated on May 19, 2026.

Analyst Ratings

The average analyst rating for Chemomab Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingSep '25Oct '25Nov '25Dec '25Mar '26May '26
Strong Buy111111
Buy111111
Hold000000
Sell000000
Strong Sell000000
Total222222

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Maxim Group
Maxim Group
Buy
Maintains
$5
BuyMaintains$5+222.58%May 19, 2026
Oppenheimer
Oppenheimer
Buy
Maintains
$25
BuyMaintains$25+1,512.90%May 15, 2026

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.02
from -0.02
EPS Next Year
-0.03
from -0.02
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
------
Operating Income
-12.37M-28.53M-25.46M-14.74M-9.57M-11.84M
Net Income
-12.48M-27.65M-24.22M-13.95M-9.00M-11.76M
EPS
-----0.02-0.02
Free Cash Flow
-6.07M-10.87M-15.49M-10.86M-8.20M-23.29M
No. Analysts
-----2
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
Highn/a
Avgn/a
Lown/a

Revenue Growth

Revenue Growth20272028
High-
Avg-
Low-

EPS Forecast

EPS202620272028
High-
Avg-0.02
Low-

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-